Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed a Form 8-K on December 6, 2022, reporting the entry into a material definitive agreement. The company is a Delaware corporation headquartered in Waltham, Massachusetts, focused on pharmaceutical development.
Key Financial Metrics and Transaction Details
This filing details a primary equity offering rather than periodic financial results. Key transaction metrics include:
- Shares Issued: 6,818,182 shares of Common Stock.
- Offering Price: $22.00 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 1,022,727 additional shares.
- Gross Proceeds: Approximately $150.0 million (base); approximately $172.5 million if the over-allotment option is fully exercised.
- Underwriters: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Cowen and Company, LLC.
- Expected Closing: On or about December 9, 2022.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels; this document solely reports the capital raise event.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of new shares and the influx of capital. To support the offering, the Company and all directors and executive officers agreed to a 60-day lock-up period, prohibiting the sale or transfer of Common Stock without the written consent of Goldman Sachs & Co. LLC, effective from December 6, 2022.
Outlook, Risks, and Management Commentary
The offering is being made pursuant to a shelf registration statement (Form S-3) effective since March 24, 2021. The Underwriting Agreement contains customary representations, warranties, covenants, and indemnification obligations. The filing notes that the agreement's terms are subject to limitations agreed upon by the contracting parties and are qualified by reference to the full agreement attached as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date and whether the underwriters exercised the 1,022,727 share over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Confirm the net proceeds to the company after deducting underwriting discounts and commissions, which are not detailed in this summary.
- Check subsequent filings for the updated cash position and how the proceeds will be allocated to clinical trials or operations.